株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

イオンチャネル型グルタミン酸塩受容体NMDA 2B:パイプライン製品の分析

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 365747
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
イオンチャネル型グルタミン酸塩受容体NMDA 2B:パイプライン製品の分析 Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H1 2019
出版日: 2019年04月23日 ページ情報: 英文 50 Pages
概要

当レポートでは、イオンチャネル型グルタミン酸塩受容体NMDA 2Bを標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

イオンチャネル型グルタミン酸塩受容体NMDA 2B 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • BioCrea GmbH
  • Bristol-Myers Squibb Company
  • Cerecor Inc.
  • Johnson & Johnson
  • Luc Therapeutics, Inc.
  • NeurOp, Inc
  • Novartis AG
  • UCB S.A.

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Indication, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Pipeline by Cadent Therapeutics Inc, H1 2019
  • Pipeline by Cerecor Inc, H1 2019
  • Pipeline by Johnson & Johnson, H1 2019
  • Pipeline by NeurOp Inc, H1 2019
  • Pipeline by Novartis AG, H1 2019
  • Pipeline by Shionogi & Co Ltd, H1 2019
  • Dormant Projects, H1 2019
  • Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development by Stage of Development, H1 2019
  • Number of Products under Development by Therapy Areas, H1 2019
  • Number of Products under Development by Top 10 Indications, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
目次
Product Code: GMDHC1831TDB

Summary:

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H1 2019, outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

The molecules developed by companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Dermatology which include indications Acute Ischemic Stroke, Autism, Burns, Cardiac Arrest, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Ischemic Stroke, Major Depressive Disorder, Myocardial Infarction, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Obsessive-Compulsive Disorder, Orthostatic Hypotension, Pain, Subarachnoid Hemorrhage, Traumatic Brain Injury, Traumatic Spinal Cord Injury and Treatment Resistant Depression.

Furthermore, this report also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
  • The report reviews Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview
    • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Co
    • Cadent Therapeutics Inc
    • Cerecor Inc
    • Johnson & Johnson
    • NeurOp Inc
    • Novartis AG
    • Shionogi & Co Ltd
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles
    • BMS-986163 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAD-8688 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ifenprodil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-0808 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-10679 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rislenemdaz - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize NR2B for Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA2B for Chronic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products
  • Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 15, 2019: Cerecor announces CERC-301 granted U.S. patent
      • Aug 01, 2018: Cerecor announces first patient enrolled in phase I trial for neurogenic orthostatic hypotension (noh) in Parkinson's disease
      • Apr 12, 2018: NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679
      • Oct 17, 2017: Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
      • Jul 24, 2017: NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
      • Nov 29, 2016: Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
      • Sep 21, 2016: Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
      • May 16, 2016: GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000
      • Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
      • Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect
      • Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder
      • Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum
      • Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study
      • Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder
      • Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top